Is Abivax S.A. (ABVX.PA) a Buy, Sell, or Hold?
PAR : ABVX.PA
Abivax S.A.
$113.2 EUR
$0.4 (0.35%)
- Volume
- 120.82K
- Average Volume
- 318.69K
- Market Capitalization
- $8.31B
- P/E Ratio
- -23.44
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $139.00
- Year Low
- $52.80
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.75
Company Overview
PAR
Marc de Garidel
Biotechnology
Healthcare
ABVX.PA
80
FR
EUR
Liquidity Metrics
0.10
8.75
8.75
8.20
0.00
Sales & Valuation
-$
0.00
17.29
-51.24
-2.33
Profitability
-$4.83
-$336.1M
0.00%
0.00%
-165.19%
-57.52%
P/E Metrics
-23.44
0.39
0.39
Analyst Price Target & Rating
2/5
0 Analysts
%
Financial Health Scores
36.24
3/9
$488.22M
$584.34M
$129.14M
-$422.99M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Ida Hatoum | Chief People & Compliance Officer |
| Hema Keshava | Senior Vice President of Finance |
| Kevin Shan | Vice President & Global Head of Biometrics |
| Mary Mantock | Senior VP & Global Head of Regulatory Affairs |
| Didier Blondel | EVice President, Chief Financial Officer & Board Secretary |
| Jerome Denis | Executive Vice President of Process Development & Manufacturing |
| Marc de Garidel | Chief Executive Officer & Director |
| Chris Rabbat | Vice President & Global Head of Medical Affairs |
| Patrick Malloy | Senior VP & Head of Investor Relations |
| Pierre Courteille | Chief Business Officer |
Poll Results
No votes yet today — be the first to share your view!
About Abivax S.A. (PAR:ABVX.PA) Stock
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syn ... cytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Frequently Asked Questions
-
What is the current Abivax S.A. (ABVX.PA) stock price?
-
Abivax S.A.(PAR:ABVX.PA) stock price is $113.2 in the last trading session. During the trading session, ABVX.PA stock reached the peak price of $139 while $52.8 was the lowest point it dropped to. The percentage change in ABVX.PA stock occurred in the recent session was 0.35% while the dollar amount for the price change in ABVX.PA stock was $0.4.
-
ABVX.PA's industry and sector of operation?
-
The PAR listed ABVX.PA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ABVX.PA?
-
Ida Hatoum | Chief People & Compliance Officer
Hema Keshava | Senior Vice President of Finance
Kevin Shan | Vice President & Global Head of Biometrics
Mary Mantock | Senior VP & Global Head of Regulatory Affairs
Didier Blondel | EVice President, Chief Financial Officer & Board Secretary -
How many employees does ABVX.PA have?
-
Number of ABVX.PA employees currently stands at 80. ABVX.PA operates from 7-11 Boulevard Haussmann, Paris, IF 75008, FR.
-
Link for ABVX.PA official website?
-
Official Website of ABVX.PA is: https://www.abivax.com
-
How do I contact ABVX.PA?
-
ABVX.PA could be contacted at phone #33 1 53 83 08 41 and can also be accessed through its website. ABVX.PA operates from 7-11 Boulevard Haussmann, Paris, IF 75008, FR.
-
How many shares of ABVX.PA are traded daily?
-
The average number of ABVX.PA shares traded daily for last 3 months was 318.69K.
-
What is the market cap of ABVX.PA currently?
-
The market value of ABVX.PA currently stands at $8.31B with its latest stock price at $113.2